204 related articles for article (PubMed ID: 35416119)
1. The first gene therapy for
Ferraz Sallum JM; Godoy J; Kondo A; Kutner JM; Vasconcelos H; Maia A
Ophthalmic Genet; 2022 Aug; 43(4):550-554. PubMed ID: 35416119
[TBL] [Abstract][Full Text] [Related]
2. Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis.
Gange WS; Sisk RA; Besirli CG; Lee TC; Havunjian M; Schwartz H; Borchert M; Sengillo JD; Mendoza C; Berrocal AM; Nagiel A
Ophthalmol Retina; 2022 Jan; 6(1):58-64. PubMed ID: 33838313
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials.
Maguire AM; Russell S; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; Marshall KA; McCague S; Reichert H; Davis M; Simonelli F; Leroy BP; Wright JF; High KA; Bennett J
Ophthalmology; 2019 Sep; 126(9):1273-1285. PubMed ID: 31443789
[TBL] [Abstract][Full Text] [Related]
4. Current Management of Patients with RPE65 Mutation-Associated Inherited Retinal Degenerations in Europe: Results of a Multinational Survey by the European Vision Institute Clinical Research Network.
Lorenz B; Tavares J; van den Born LI; Marques JP; Scholl HPN;
Ophthalmic Res; 2021; 64(5):740-753. PubMed ID: 33684911
[TBL] [Abstract][Full Text] [Related]
5. Voretigene Neparvovec: A Review in RPE65 Mutation-Associated Inherited Retinal Dystrophy.
Kang C; Scott LJ
Mol Diagn Ther; 2020 Aug; 24(4):487-495. PubMed ID: 32535767
[TBL] [Abstract][Full Text] [Related]
6. Real-world outcomes of voretigene neparvovec treatment in pediatric patients with RPE65-associated Leber congenital amaurosis.
Deng C; Zhao PY; Branham K; Schlegel D; Fahim AT; Jayasundera TK; Khan N; Besirli CG
Graefes Arch Clin Exp Ophthalmol; 2022 May; 260(5):1543-1550. PubMed ID: 35001204
[TBL] [Abstract][Full Text] [Related]
7. [Inherited retinal dystrophy: first results of RPE65 gene replacement therapy in Russia].
Kadyshev VV; Zolnikova IV; Khalanskaya OV; Stepanova AA; Kutsev SI
Vestn Oftalmol; 2022; 138(4):48-57. PubMed ID: 36004591
[TBL] [Abstract][Full Text] [Related]
8. Single Center Experience with Voretigene Neparvovec Gene Augmentation Therapy in RPE65 Mutation-Associated Inherited Retinal Degeneration in a Clinical Setting.
Lorenz B; Künzel SH; Preising MN; Scholz JP; Chang P; Holz FG; Herrmann P
Ophthalmology; 2024 Feb; 131(2):161-178. PubMed ID: 37704110
[TBL] [Abstract][Full Text] [Related]
9. [Gene therapy treatment based on an ophthalmic indication in hereditary retinal dystrophy caused by RPE65 biallelic gene mutation.].
Vizvári E; Smeller L; Jánossy Á; Lőrincz M; Janáky M; Tóth-Molnár E
Orv Hetil; 2022 Nov; 163(48):1923-1931. PubMed ID: 36436058
[TBL] [Abstract][Full Text] [Related]
10. Utility of In Vitro Mutagenesis of RPE65 Protein for Verification of Mutational Pathogenicity Before Gene Therapy.
Yang U; Gentleman S; Gai X; Gorin MB; Borchert MS; Lee TC; Villanueva A; Koenekoop R; Maguire AM; Bennett J; Redmond TM; Nagiel A
JAMA Ophthalmol; 2019 Dec; 137(12):1381-1388. PubMed ID: 31580392
[TBL] [Abstract][Full Text] [Related]
11. Subretinal Injection of Voretigene Neparvovec-rzyl in a Patient With RPE65-Associated Leber's Congenital Amaurosis.
Hussain RM; Tran KD; Maguire AM; Berrocal AM
Ophthalmic Surg Lasers Imaging Retina; 2019 Oct; 50(10):661-663. PubMed ID: 31671202
[TBL] [Abstract][Full Text] [Related]
12. Short-Term Outcomes of the First in Vivo Gene Therapy for RPE65-Mediated Retinitis Pigmentosa.
Kwak JJ; Kim HR; Byeon SH
Yonsei Med J; 2022 Jul; 63(7):701-705. PubMed ID: 35748082
[TBL] [Abstract][Full Text] [Related]
13. Short term morphological rescue of the fovea after gene therapy with voretigene neparvovec.
Kortüm FC; Kempf M; Jung R; Kohl S; Ott S; Kortuem C; Sting K; Stingl K
Acta Ophthalmol; 2022 May; 100(3):e807-e812. PubMed ID: 34289237
[TBL] [Abstract][Full Text] [Related]
14. Voretigene Neparvovec Gene Therapy in Clinical Practice: Treatment of the First Two Italian Pediatric Patients.
Testa F; Melillo P; Della Corte M; Di Iorio V; Brunetti-Pierri R; Citro A; Ferrara M; Karali M; Annibale R; Banfi S; Rossi S; Simonelli F
Transl Vis Sci Technol; 2021 Aug; 10(10):11. PubMed ID: 34554209
[TBL] [Abstract][Full Text] [Related]
15. Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 3 and 4 Years.
Maguire AM; Russell S; Chung DC; Yu ZF; Tillman A; Drack AV; Simonelli F; Leroy BP; Reape KZ; High KA; Bennett J
Ophthalmology; 2021 Oct; 128(10):1460-1468. PubMed ID: 33798654
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial.
Russell S; Bennett J; Wellman JA; Chung DC; Yu ZF; Tillman A; Wittes J; Pappas J; Elci O; McCague S; Cross D; Marshall KA; Walshire J; Kehoe TL; Reichert H; Davis M; Raffini L; George LA; Hudson FP; Dingfield L; Zhu X; Haller JA; Sohn EH; Mahajan VB; Pfeifer W; Weckmann M; Johnson C; Gewaily D; Drack A; Stone E; Wachtel K; Simonelli F; Leroy BP; Wright JF; High KA; Maguire AM
Lancet; 2017 Aug; 390(10097):849-860. PubMed ID: 28712537
[TBL] [Abstract][Full Text] [Related]
17. Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence.
Kolesnikova M; Lima de Carvalho JR; Parmann R; Kim AH; Mahajan VB; Tsang SH; Sparrow JR
Mol Genet Genomic Med; 2022 Nov; 10(11):e2038. PubMed ID: 36225124
[TBL] [Abstract][Full Text] [Related]
18. An Update on Gene Therapy for Inherited Retinal Dystrophy: Experience in Leber Congenital Amaurosis Clinical Trials.
Chiu W; Lin TY; Chang YC; Isahwan-Ahmad Mulyadi Lai H; Lin SC; Ma C; Yarmishyn AA; Lin SC; Chang KJ; Chou YB; Hsu CC; Lin TC; Chen SJ; Chien Y; Yang YP; Hwang DK
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926102
[TBL] [Abstract][Full Text] [Related]
19. Voretigene neparvovec-rzyl for treatment of
Ciulla TA; Hussain RM; Berrocal AM; Nagiel A
Expert Opin Biol Ther; 2020 Jun; 20(6):565-578. PubMed ID: 32149547
[No Abstract] [Full Text] [Related]
20. Gene therapy for RPE65-related retinal disease.
Miraldi Utz V; Coussa RG; Antaki F; Traboulsi EI
Ophthalmic Genet; 2018 Dec; 39(6):671-677. PubMed ID: 30335549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
